×
About 4,704 results
Evidence Mounts for Bariatric Benefit in Obesity-Related Cancer
https://www.medscape.com/viewarticle/921110
Medscape Busko, M

Nov 11th, 2019 - Two studies that provide further support for a potential benefit of a reduced risk of obesity-related cancers post-bariatric surgery were presented here at Obesity Week 2019.

Pediatric Metabolic and Bariatric Surgery: Evidence, Barriers, and Best Practices
https://pediatrics.aappublications.org/content/early/2019/10/24/peds.2019-3223
Pediatrics Armstrong, S. et. al.

Oct 27th, 2019 - Severe obesity among youth is an “epidemic within an epidemic” and portends a shortened life expectancy for today’s children compared with those of their parents’ generation. Severe obesity has outpaced less severe forms of childhood obesity in prevalence, and it disproportionately affects adolescents. Emerging evidence has linked severe obesity to the development and progression of multiple co...

Chronic inflammatory liver diseases and coffee intake
https://journals.lww.com/co-clinicalnutrition/Abstract/publishahead/Chronic_inflammatory_liver_diseases_and_coffee.99131.aspx
Current Opinion in Clinical Nutrition & Metabolic Care; Contaldo, F. et. al.

Jun 17th, 2019 - Purpose of review To review the healthy protective effects of coffee against several metabolic diseases and some types of cancer. In this short review, the possible preventive and/or therapeutic actions of coffee on liver function is focused. Recent findings The protective mechanisms of coffee are various and because of several components with anti-inflammatory and antioxidant properties in ...

FDA approves ramucirumab for hepatocellular carcinoma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma

May 9th, 2019 - On May 10, 2019, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib.

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
https://jnccn.org/view/journals/jnccn/17/4/article-p302.xml
Benson, A. et. al.

Mar 31st, 2019 - Incidence and mortality rates for cancer overall are declining, but both incidence and mortality rates for hepatocellular carcinoma (HCC) are increasing.1,2 Risk factors for development of HCC include infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), and cirrhosis of the liver (eg, alcohol cirrhosis).3 Metabolic disorders (ie, obesity, diabetes, impaired glucose metabolism,...

Appendicitis - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK493193/

Feb 21st, 2019 - Appendicitis is inflammation of the vermiform appendix. This is a hollow organ located at the tip of the cecum, usually in the right lower quadrant of the abdomen.

Hepatitis, Nonalcoholic Steatohepatitis
https://www.ncbi.nlm.nih.gov/books/NBK470243/
Sharma, B. et. al.

Jan 31st, 2019 - Nonalcoholic, fatty liver disease (NAFLD) is defined as the ectopic accumulation of fat in the liver (hepatic steatosis) when no other causes of secondary, liver fat accumulation are present. As minor deposition of fat can occur in healthy adults, deposition of fat in at least 5% of hepatocytes is considered pathologic. Nonalcoholic steatohepatitis (NASH) is diagnosed via a liver biopsy when th...

Ramucirumab After Sorafenib in Patients With Advanced HCC and Increased α-Fetoprotein Concentrations
https://www.practiceupdate.com/c/78793/2/1
Grothey, A.

Jan 22nd, 2019 - The landscape of systemic therapy of hepatocellular carcinoma (HCC) has dramatically changed in the last 5 years with the introduction of various active agents into clinical pathways. The latest addition of agents with proof-of-efficacy in HCC is ramucirumab, an antibody against VEGF-R2. The published results of the REACH-2 trial in patients with prior sorafenib therapy demonstrate increased ov...

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
https://www.thelancet.com/action/showPdf?pii=S1470-2045%2818%2930937-9
Zhu, A. et. al.

Jan 17th, 2019 - Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.

Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study
https://www.gastrojournal.org/article/S0016-5085(19)30057-5/pdf
Singal, A. et. al.

Jan 16th, 2019 - Background & Aims There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.

Appendicitis - Merck Manual
https://www.merckmanuals.com/professional/gastrointestinal-disorders/acute-abdomen-and-surgical-gastroenterology/appendicitis

Nov 30th, 2018 - Appendicitis is acute inflammation of the vermiform appendix, typically resulting in abdominal pain, anorexia, and abdominal tenderness. Diagnosis is clinical, often supplemented by CT or ultrasonography. Treatment is surgical removal of the appendix

ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30–35 kg/m2)
https://asmbs.org/app/uploads/2018/08/PIIS1550728918302934-Low-BMI.pdf

Jul 31st, 2018 - The American Society for Metabolic and Bariatric Surgery (ASMBS) issued a position statement on the role of bariatric surgery in class I obesity in 2012 [1]. That statement was developed in response to inquiries made to the ASMBS by society members, physicians, patients, hospitals, health insurance payers, policymakers, and the media regarding the safety and efficacy of bariatric surgery f...

Obesity Ties to Cancer, Diabetes Showcased in Vegas Meeting
https://www.medscape.com/viewarticle/920787

Nov 3rd, 2019 - LAS VEGAS — In this glitzy city where lady luck lurks, it is a sure bet that attendees at Obesity Week 2019, this year's joint meeting of The Obesity Society and American Society for Metabolic and Bariatric Surgery (ASMBS), will learn new things from the latest scientific evidence in the field. Medscape Medical News interviewed the ASMBS president and two program planners from The Obesity Socie...

'I Have Had My Eyes Gouged': What We Heard This Week
https://www.medpagetoday.com/emergencymedicine/emergencymedicine/83101

Nov 1st, 2019 - "I have had my eyes gouged; I have been shoved and punched. I have seen one intern literally knocked out cold by someone who sucker-punched him." -- Ken Marriott, MD, of the University of Texas Health Science Center, commenting on a study suggesting violence against emergency department staff is a global problem. "Our kids, our nation, and our world face a grim future." -- Christopher Bolling, ...

Bariatric Surgery Not Necessarily Cost-Effective in Short-Term
https://www.medpagetoday.com/primarycare/obesity/83070

Oct 31st, 2019 - Bariatric surgery may not necessarily be associated with lower healthcare costs in the long-term, a new study suggested. Among U.S. veterans with severe obesity, those who opted to undergo bariatric surgery saw about $25,900 more in cumulative healthcare expenditures in the ten years following their operation versus matched nonsurgical controls ($143,248 vs $117,378, respectively), reported Mat...

Second Deadly Risk; Oncologist Shortage; Searching for Cancer in a Haystack
https://www.medpagetoday.com/hematologyoncology/breastcancer/83058

Oct 30th, 2019 - Many women survive breast cancer only to face another health threat -- heart disease. (CBS News, MSN.com) Tiny implantable cancer cell "decoys" might offer an alternative to more invasive tumor biopsies. (University of Michigan) A preliminary study of a blood test for patients with glioblastoma showed that higher levels of circulating tumor DNA correlated with a shorter progression-free surviva...

Reduction in Melanoma After Bariatric Surgery ― Really?
https://www.medscape.com/viewarticle/920580

Oct 29th, 2019 - Bariatric surgery and the weight loss that it induces are associated with a markedly reduced risk for skin cancer, including melanoma, according to a new analysis from the Swedish Obese Subjects (SOS) study. In an earlier report from this study, Swedish researchers found that bariatric surgery was associated with a reduced risk for female-specific cancers, including breast, endometrial, ovarian...

Markers on Ultrasound May Predict HCC in Cirrhosis Patients
https://www.medpagetoday.com/gastroenterology/generalhepatology/83005

Oct 29th, 2019 - In cirrhosis patients at risk for hepatocellular carcinoma (HCC), differences in contrast uptake during an initial ultrasound and a nodule's growth rate on follow-up imaging may be noninvasive diagnostic predictors of progression to carcinoma, a small retrospective study from China suggested. In a sample of 39 patients with confirmed cirrhotic nodules on contrast-enhanced ultrasound (CEUS), a c...

AAP Recommends Bariatric Surgery for Severely Obese Kids
https://www.medscape.com/viewarticle/920527

Oct 28th, 2019 - NEW ORLEANS — With some 4.5 million children and adolescents in the US with severe obesity, the American Academy of Pediatrics (AAP) has issued a new policy statement calling for greater access to bariatric surgery, one of the few strategies shown to be effective in treating severe obesity in children. The policy statement, entitled "Pediatric Metabolic and Bariatric Surgery: Evidence, Barriers...

Roche pushes late-comer Tecentriq as new liver cancer option
https://www.reuters.com/article/us-roche-tecentriq/roche-pushes-late-comer-tecentriq-as-new-liver-cancer-option-idUSKBN1X00EV

Oct 21st, 2019 - FILE PHOTO: Swiss drugmaker Roche's logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) - Roche’s Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker’s strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals. Roche said on Monda...